Lifting and longevity: is 1 hour a week really the limit?

Episode Overview

• Drs. Jordan Feigenbaum and Austin Baraki host a monthly listener Q&A ("Direct Line") addressing four complex questions across exercise science, pharmacology, nutrition, and chronic illness management, while noting the discussion is for infotainment purposes only and promoting their Barbell Medicine Plus and Premium memberships.
• First, the hosts examine epidemiological claims that the longevity benefits of strength training vanish after 60 minutes per week, breaking down methodological flaws in older meta-analyses and contrasting them with newer longitudinal data.
• Next, they explore the psychiatric and hedonic effects of GLP-1 receptor agonists, weighing large-scale regulatory safety reviews against clinical observations of motivational flattening and reduced substance cravings.
• They then dissect the "is a calorie just a calorie" debate in the context of high-protein and ketogenic diets, distinguishing between the laws of thermodynamics and the behavioral realities of human nutrition.
• Finally, the episode provides a compassionate, evidence-based framework for modifying resistance training for individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) to prevent post-exertional crashes.

Key Concepts

• Resistance Training Volume and Longevity: While a 2022 meta-analysis of 16 cohort studies (Momma et al.) showed a 15% reduction in all-cause mortality from any lifting (and ~40% when combined with cardio, alongside Dankel et al. showing ~23% for meeting guidelines), its finding that benefits drift toward neutral past 60 minutes per week is a statistical artifact caused by sparse high-volume data and a single baseline questionnaire. A 2026 Harvard study (Zhang et al.) following ~147,000 people for up to 30 years with repeated measurements showed longevity benefits actually rise up to 2 hours per week before leveling off, never turning into harm.
• Limitations of Time-Based Lifting Metrics: Measuring resistance training purely in "minutes per week" is clinically unhelpful because it ignores training load, exercise selection, and individual genetic sensitivity. Unlike ultra-endurance aerobic exercise—where extreme volumes are associated with atrial fibrillation and coronary artery calcification—high-volume lifting does not carry cardiovascular mortality risks, though returns strictly for general health plateau around 90 to 120 minutes per week.
• GLP-1s, Psychiatric Safety, and Hedonic Drive: Despite media concerns about depression, the STEP trials showed slightly better depression scores on semaglutide versus placebo, and a January 2026 FDA review of 91 placebo-controlled trials (~108,000 patients) plus over 2 million real-world users found no increased risk of suicidal ideation, prompting both the FDA and European regulators to remove the warning. Meanwhile, randomized trials (Hendershot et al., 2025 in JAMA Psychiatry with 48 adults in a "bar lab," and a 2026 Lancet replication) demonstrate that low-dose semaglutide significantly reduces alcohol consumption, alcohol cravings, and cigarette smoking.
• GLP-1 Anhedonia and Hormonal Effects: While effects on hobbies like gaming remain unstudied ("we genuinely don't know"), Dr. Baraki observes that a small minority of patients experience flattened mood or motivation (anhedonia), primarily at the highest doses and more frequently with tirzepatide (Zepbound) than semaglutide (Wegovy/Ozempic), possibly due to the unsettled neurobiology of the GIP component. Regarding libido, Dr. Feigenbaum notes that losing visceral fat on GLP-1s generally increases endogenous testosterone in men, though severe caloric restriction can cause temporary fatigue that masks this benefit.
• Energy Balance vs. Behavioral Dynamics in High-Protein and Keto Diets: A calorie is 100% a unit of energy measurement, meaning weight loss on high-protein or ketogenic diets still requires a caloric deficit; however, simply advising patients to "eat less, move more" fails because energy intake and expenditure are dynamic systems. While protein has a higher thermic effect of food, its impact on total daily energy expenditure is uncertain and modest at best; protein primarily aids weight loss by displacing higher-calorie foods (Americans average 1 to 1.1 g/kg/day mostly from ultra-processed, high-fat sources).
• Methodological Flaws in "Equal Calorie" Diet Studies: Studies claiming high-protein or ketogenic diets cause superior fat loss at equal calories rely on flawed measurements; for example, a 12-week trial by Haghighat et al. (2020) reported body composition advantages on an "euenergetic" high-protein diet, but Table 1 reveals the high-protein group accidentally ate ~90 to 130 fewer calories per day, cut carbs (shedding water and glycogen), and measured body fat via Bioelectrical Impedance Analysis (BIA), whose error margin swallowed the results. Similarly, controlled data show keto's weight-loss advantage stems from spontaneous calorie reduction and disappears by 6 to 12 months.
• Pathophysiology of ME/CFS and Post-Exertional Malaise (PEM): As defined by a 2015 National Academy of Sciences panel, the hallmark of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is PEM—a multi-day crash out of proportion to effort. An identical twin study (ibanez et al., 2019) and larger group replications prove this is physiological: on day two of a consecutive hard exercise test, a healthy twin repeats day-one performance, whereas the twin with ME/CFS suffers a 13% drop at the anaerobic threshold, rendering historical medical advice to use forced "graded exercise therapy" actively harmful.

Quotes

• At 5:15 - "It's like if somebody tells me I strength trained for 30 minutes or 60 minutes or two hours or four hours, I still don't particularly know what you did. And I don't know whether it was appropriate for your level of adaptation, I don't know what you're counting as resistance training, I don't know any of the other like variables to determine was this like a reasonable strength training program in general and was a reasonable match for you and your level of adaptation and your and your goals." - Dr. Austin Baraki explaining why epidemiological studies measuring lifting purely by duration are clinically unhelpful.
• At 7:10 - "How strong of a case can I make for getting them from doing nothing to doing 30 minutes a week? A very, very, very strong case. From there, how strong of a case can I make for getting them from doing, say, 30 or 60 minutes up to 60 to 90 minutes or, you know, two hours a week? I can still make a pretty good case for that, right? If they're already doing two hours a week of, say, strength training, how much stronger of a case can I make for them pushing it to three hours, to four hours? I think it is fairly obvious to most people that purely from a health standpoint, the strength of my case is going to diminish for health outcomes." - Dr. Austin Baraki outlining the diminishing marginal health returns of strength training past two hours per week.
• At 15:02 - "In early 2026, the FDA asked for the suicidal ideation warning to be removed after reviewing 91 placebo-controlled trials covering about 108,000 patients, plus over 2 million real-world users, and the European regulatory body landed in the same place. So this Ozempic makes you depressed sort of claim, yeah, we can kind of we can kind of nip that in the bud." - Dr. Jordan Feigenbaum citing massive regulatory reviews that cleared GLP-1 medications of depression and suicide risks.
• At 16:12 - "More often when I have seen more of this kind of suppression of mood, of interest, of motivation, it tends to arise at the highest doses and more often with Zepbound than with Wegovy or or semaglutide." - Dr. Austin Baraki sharing clinical observations on when GLP-1-induced anhedonia occurs.
• At 25:46 - "100% of the time, a calorie is just a calorie because it's a unit, just like a second or a meter or, you know, measures time or distance, a calorie is a unit of measure for energy. That said, you know, calories in, calories out, is a calorie just a calorie, I think what people are getting at when they're, I mean, trying to poke holes in that relationship is that on either side, calories in, calories out, both sides are dynamic, and just stating the relationship is not terribly helpful advice for most folks. And I think that's fine. Two things can be true. A calorie can just be a calorie, but the advice to just eat less, move more, or it's all just about energy balance, may not be great advice." - Dr. Jordan Feigenbaum reconciling the physics of thermodynamics with practical nutrition coaching.
• At 36:27 - "Both did a hard exercise test two days in a row. The healthy twin repeated the performance on day two just fine. The twin, though, with chronic fatigue syndrome dropped about 13% at the anaerobic threshold test on the second day, basically the point where the effort tips from manageable to much harder. And that's not just a twin curiosity. Run the same two-day test on groups of these patients and the same pattern holds. They show a bigger drop-off on day two than healthy people do. You can't really talk yourself out of that." - Dr. Jordan Feigenbaum detailing objective physiological proof of post-exertional malaise in ME/CFS patients.
• At 37:51 - "As far as her boyfriend goes, he's half right. Look, lifting weights in bed is probably not going to build as much muscle or strength as like going to a gym and doing a quote real training session, but that's not really the point. It's better than doing nothing, thing one, and two, she's getting something out of it. For exercise to really accomplish nothing, it has to be so submaximal, so light, so easy that it does not challenge her or the person at any level, which is pretty hard to do." - Dr. Jordan Feigenbaum validating modified, low-threshold resistance exercise for individuals managing severe chronic fatigue.

Takeaways

• Structure training volume for your specific goals: Aim for at least 30 to 120 minutes of resistance training per week alongside cardiovascular conditioning to maximize longevity and health adaptations; if you lift beyond 2 hours per week for performance or enjoyment, manage your programming to avoid musculoskeletal injury and ensure lifting does not crowd out all aerobic conditioning.
• Manage GLP-1 side effects under medical supervision: Never purchase gray-market "research" peptides due to dosing and contamination risks; if you experience flattened motivation or mood on high-dose prescribed GLP-1s (such as 15 mg of tirzepatide), work with your prescribing clinician to lower the dose by ~5 mg (e.g., to 10 mg), consider augmenting with an activating medication like bupropion, or discontinue the drug knowing the effects are fully reversible.
• Optimize protein and monitor biomarkers on restrictive diets: Increase lean protein intake from 0.6–0.8 g/kg/day up to 1.6–1.8 g/kg/day alongside resistance training to build lean mass and naturally displace higher-calorie foods (noting that pushing to 2.2+ g/kg/day adds no extra muscle benefit); if using a ketogenic diet for weight loss, check blood lipids to ensure high saturated fat intake isn't elevating LDL cholesterol or triglycerides, and negotiate swapping in unsaturated fats (seafood, plants) and 30 to 40 grams of daily fiber if labs worsen.
• Pace resistance training within your "energy envelope" for ME/CFS: Avoid forced weekly progression; instead, cap workouts at 2 exercises per session, extend rest periods to 4–6 minutes between sets, keep effort low at RPE 5–6, use double progression (e.g., 6 to 10 reps, adding weight only after hitting 10 reps across all sets), substitute isometrics or bed-based exercises on low-energy days, and log both session RPE (1–10) and symptom responses at 24, 48, and 72 hours post-workout.